Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: Deciphering the prognostic features of bladder cancer through gemcitabine resistance and immune-related gene analysis and identifying potential small molecular drug PIK-75

Fig. 5

Implications of GIRS for immunotherapy and chemotherapy response prediction in three therapeutic cohorts. A Distribution of GIRS for patients exhibiting different immunotherapeutic responses in the IMvigor210. B Kaplan–Meier curve analysis of OS between high and low GIRS subgroups in the IMvigor210. C Time-dependent ROC analysis for predicting OS in the IMvigor210. D GIRS score in the CR/PR group and SD/PD group in IMvigor210. Statistical comparisons were conducted using the t-test (p = 5.3e−05). E Boxplot displayed the GIRS signature in patients with different immunotherapy responses in the IMvigor210. F Distribution of GIRS for patients exhibiting different immunotherapeutic responses in the GSE91061. G Boxplot displayed the GIRS signature in patients with different immunotherapy responses in the GSE91061. H Kaplan–Meier curve analysis of OS between high and low GIRS subgroups in the GSE91061. I Time-dependent ROC analysis for predicting OS in the GSE91061. J GIRS score in the CR/PR group and SD/PD group. Statistical comparisons were conducted using the t-test (p = 0.00019). K Boxplot displayed the GIRS signature in patients with different immunotherapy responses in the GSE52219

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us